STOCK TITAN

Caris Life Sciences Publishes Study Showing Whole Exome Measurement of Tumor Mutational Burden Results in Increased Overall Survival Compared to Estimates from Targeted Gene Panels

Rhea-AI Impact
(Moderate)
Rhea-AI Sentiment
(Neutral)
Tags

Caris Life Sciences (NASDAQ:CAI) reported study results showing that ultra-deep Whole Exome Sequencing (WES) measurement of tumor mutational burden (TMB) better predicts pembrolizumab benefit than targeted gene panels.

Among 26,756 pembrolizumab-treated patients, targeted panels misclassified TMB in 10–15% of cases, while WES-based TMB was linked to longer overall survival in key subgroups.

Caris’ FDA-approved MI Cancer Seek assay delivers simultaneous WES and Whole Transcriptome Sequencing with quantitative TMB reporting for solid tumors.

Loading...
Loading translation...

AI-generated analysis. Not financial advice.

Positive

  • Study analyzed 26,756 pembrolizumab-treated patients using Caris’ clinico-genomic database
  • Targeted panels showed 10–15% TMB discordance; WES-based TMB predicted survival more accurately
  • In TMB-reliant subset (n=3,981), WES TMB-High cases had about five months longer median overall survival
  • Caris’ MI Cancer Seek received FDA approval in November 2024 as a WES/WTS companion diagnostic with TMB reporting

Negative

  • None.

News Market Reaction – CAI

-1.30%
17 alerts
-1.30% News Effect
+3.5% Peak in 24 min
-$64M Valuation Impact
$4.86B Market Cap
0.3x Rel. Volume

On the day this news was published, CAI declined 1.30%, reflecting a mild negative market reaction. Argus tracked a peak move of +3.5% during that session. Our momentum scanner triggered 17 alerts that day, indicating notable trading interest and price volatility. This price movement removed approximately $64M from the company's valuation, bringing the market cap to $4.86B at that time.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

TMB miscalculation rate: 10–15% Pembrolizumab cohort size: 26,756 patients TMB-reliant subset size: 3,981 patients +4 more
7 metrics
TMB miscalculation rate 10–15% Patients where targeted panels miscalculate tumor mutational burden
Pembrolizumab cohort size 26,756 patients Caris real-world clinico-genomic database used in WES vs panel study
TMB-reliant subset size 3,981 patients Subset with tumor types lacking disease-specific checkpoint inhibitor indications
Survival benefit difference about five months Median OS advantage for WES TMB-High vs panel TMB-High discordant cases
MI Cancer Seek FDA approval date November 2024 Approval of WES/WTS-based assay with CDx indications
Pembrolizumab eligibility error 10–15% of patients Patients whose eligibility is incorrectly determined by targeted panels
Tumor types pan-tumor biomarker TMB used across tumor types to determine pembrolizumab eligibility

Market Reality Check

Price: $15.07 Vol: Volume 8,424,442 is 3.94x...
high vol
$15.07 Last Close
Volume Volume 8,424,442 is 3.94x the 20-day average of 2,136,571, indicating heavy trading ahead of this publication. high
Technical Shares at 16.105 are trading below the 200-day MA of 26.25 and sit 71.25% below the 52-week high, only 2.51% above the 52-week low.

Peers on Argus

CAI showed a -18.6% move with elevated volume, while key biotech peers were mixe...

CAI showed a -18.6% move with elevated volume, while key biotech peers were mixed: MDGL -4.67%, HALO -2.02%, versus MRNA +10.92%, ROIV +0.71%, VRNA +0.06%, suggesting a stock-specific reaction rather than a sector-wide move.

Historical Context

5 past events · Latest: May 05 (Positive)
Pattern 5 events
Date Event Sentiment Move Catalyst
May 05 AI diagnostic launch Positive +1.4% Launch of AI-powered Caris MI Clarity test for breast cancer recurrence risk.
May 04 Reimbursement milestone Positive +1.2% MolDX approval for Caris ChromoSeq expanding access to myeloid profiling.
Apr 29 AI clinical validation Positive -3.6% Peer-reviewed validation of AI signature for temozolomide benefit in GBM.
Apr 24 Conference participation Neutral +2.1% Upcoming presentations at major healthcare investor conferences.
Apr 20 Earnings scheduling Neutral +0.4% Announcement of date and webcast for Q1 2026 results.
Pattern Detected

Recent news has generally been positive with mostly modest positive price reactions; one AI clinical validation update saw a negative reaction despite constructive data.

Recent Company History

Over the last few weeks, Caris reported several constructive developments. On Apr 20, it scheduled Q1 2026 results. Subsequent news included conference presentations on Apr 24, an AI-based glioblastoma study on Apr 29, and MolDX approval for Caris ChromoSeq on May 4. On May 5, Caris launched the AI-powered MI Clarity test for breast cancer. Today’s peer-reviewed WES/TMB study extends this pattern of leveraging large clinico-genomic datasets to support therapy selection and immunotherapy decision-making.

Market Pulse Summary

This announcement details peer-reviewed evidence that ultra-deep whole exome sequencing delivers mor...
Analysis

This announcement details peer-reviewed evidence that ultra-deep whole exome sequencing delivers more accurate tumor mutational burden assessment and better prediction of pembrolizumab benefit than targeted panels, with a database of 26,756 treated patients and a key subset of 3,981 TMB‑reliant cases. It extends Caris’ recent cadence of AI and molecular profiling milestones. Investors may watch future updates on assay adoption, real-world outcomes, and how MI Cancer Seek, approved in November 2024, integrates with these findings.

Key Terms

tumor mutational burden, pembrolizumab, neoantigen, immune checkpoint inhibitors, +2 more
6 terms
tumor mutational burden medical
"Targeted gene panels miscalculate tumor mutational burden in 10–15% of patients"
Tumor mutational burden is a measure of how many genetic changes a cancer cell carries, often expressed as the number of mutations per length of DNA. Think of it like counting typos in a book: more typos can make the abnormal cells stand out to the immune system, and cancers with higher counts sometimes respond better to certain immunotherapies. For investors, TMB can affect how well drugs perform in trials, the need for companion diagnostic tests, and the commercial potential of cancer therapies.
pembrolizumab medical
"provides superior prediction of pembrolizumab immunotherapy benefit compared to estimates"
A cancer immunotherapy drug that helps the body’s immune system recognize and attack tumor cells by blocking a molecular “brake” that tumors use to hide. Investors watch it because regulatory approvals, clinical trial results, dosing rules, and competition directly affect potential sales, profit forecasts, and the valuation of companies that sell or license the drug—think of trial outcomes as checkpoint signs that can open or close a revenue road.
neoantigen medical
"interrogating every protein-coding gene mutation that may create a neoantigen"
A neoantigen is a new, abnormal protein piece that appears on a cancer cell because of a mutation and is not found on healthy cells; think of it as a unique fingerprint the immune system can recognize. It matters to investors because medicines that target neoantigens—such as personalized vaccines or immune therapies—can be highly specific, potentially more effective and safer, and therefore can shape clinical success, regulatory value and commercial potential for oncology drugs.
immune checkpoint inhibitors medical
"where TMB is the primary biomarker guiding access to immune checkpoint inhibitors"
Drugs that release the immune system’s natural “brakes,” allowing immune cells to recognize and attack cancer cells; imagine taking the safety off a guard dog so it can chase intruders. They matter to investors because they can become high-value treatments with large sales potential, but their commercial success depends on clinical trial results, regulatory approval, competition and side-effect management, which all affect a company’s valuation.
companion diagnostic (CDx) regulatory
"assay with FDA-approved companion diagnostic (CDx) indications for molecular profiling"
A companion diagnostic (CDx) is a medical test designed to identify which patients are likely to benefit from, or be harmed by, a specific drug or therapy—think of it as a key that shows which locks a particular medicine can open. For investors, a CDx matters because it shapes how many patients can use the drug, affects regulatory approval and reimbursement odds, and reduces commercial and clinical risk by targeting treatment to the right people.
clinico-genomic database medical
"Caris' large-scale, real-world clinico-genomic database, containing 26,756 patients"
A clinico-genomic database combines patients’ medical information (symptoms, treatments, outcomes) with their genetic data (DNA changes, biomarkers) into a single searchable resource. Think of it as a library that links a person’s health story to their biological “blueprint,” which helps researchers identify which therapies work for which patients. For investors, these databases can speed drug development, reduce the risk of failed trials, enable precision medicines and diagnostics, and create data-driven licensing or partnership opportunities.

AI-generated analysis. Not financial advice.

Targeted gene panels miscalculate tumor mutational burden in 10–15% of patients, directly resulting in incorrect pembrolizumab eligibility determination

IRVING, Texas, May 11, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, has published a study in Cancer Immunology, Immunotherapy demonstrating that measuring tumor mutational burden (TMB) using ultra-deep Whole Exome Sequencing (WES) provides superior prediction of pembrolizumab immunotherapy benefit compared to estimates of TMB from targeted gene panels. TMB is a pan-tumor biomarker used to determine patients' eligibility for pembrolizumab. These findings highlight the importance of testing all cancer patients with ultra-deep WES, the only truly comprehensive genomic profile for therapy selection.

The study used Caris' large-scale, real-world clinico-genomic database, containing 26,756 patients treated with pembrolizumab who were evaluable for this study. WES provides a true measurement of TMB by interrogating every protein-coding gene mutation that may create a neoantigen, in comparison to targeted panels that only estimate TMB with incomplete gene coverage.

Key findings include:

  • The analysis compared WES-measured TMB with commercially available targeted panel estimates of TMB and found discordance in 10-15% of cases, with error rates correlating to panel size.

  • In discordant cases, WES TMB more accurately predicted overall survival in pembrolizumab-treated patients than panel-based estimates.

  • In a subset of 'TMB reliant' patients (n = 3,981), for example, patients with tumor types that lack disease-specific immune checkpoint inhibitor indications, the median overall survival in discordant cases was about five months longer for WES TMB-High and panel TMB-Low compared to WES TMB-Low and panel TMB-High cases treated with pembrolizumab.

"These findings underscore the critical importance of using Whole Exome Sequencing to guide immunotherapy decisions," said Milan Radovich, PhD, Senior Vice President, Chief Scientific Officer at Caris. "Whole Exome Sequencing is the gold-standard for determination of tumor mutational burden, ensuring that patients who stand to benefit from pembrolizumab are correctly identified and that those unlikely to respond are not exposed to unnecessary treatment."

The study concludes that WES-based TMB measurements are a superior predictor of pembrolizumab benefit than panel-based TMB estimates and more reliably identify both patients who may benefit from therapy and those unlikely to respond, particularly in tumor types where TMB is the primary biomarker guiding access to immune checkpoint inhibitors.

Caris received FDA approval in November 2024 for MI Cancer Seek. This tissue-based assay is the first and only simultaneous WES and Whole Transcriptome Sequencing (WTS)-based assay with FDA-approved companion diagnostic (CDx) indications for molecular profiling of solid tumors and includes quantitative reporting of TMB.

About Caris Life Sciences
Caris Life Sciences® (Caris) is a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer actively developing and commercializing innovative solutions to transform healthcare. Through comprehensive molecular profiling (Whole Genome, Whole Exome and Whole Transcriptome Sequencing), advanced AI and machine learning, Caris has created the large-scale, multimodal clinico-genomic database and computing capability needed to analyze and further unravel the molecular complexity of disease. This convergence of next-generation sequencing, AI and machine learning technologies and high-performance computing provides a differentiated platform for developing the latest generation of advanced precision medicine diagnostic solutions for early detection, diagnosis, monitoring, therapy selection and drug development.  

Caris was founded with a vision to realize the potential of precision medicine to improve the human condition. Headquartered in Irving, Texas, Caris has offices in Phoenix, New York, Cambridge (MA), Tokyo, Japan and Basel, Switzerland. Caris or its distributor partners provide services in the U.S. and other international markets.  

Forward Looking Statements
This press release contains forward-looking statements within the meaning of the federal securities laws. All statements other than statements of historical facts contained in this press release are forward-looking statements, including statements regarding our business, solutions, plans, objectives, goals, industry trends, financial outlook and guidance. In some cases forward-looking statements can be identified by words such as "may," "will," "should," "would," "expect," "plan," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or similar expressions.   

You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in these forward-looking statements are reasonable based on information currently available to us, we cannot guarantee that the future results, discoveries, levels of activity, performance or events and circumstances reflected in forward-looking statements will be achieved or occur. Forward-looking statements involve known and unknown risks and uncertainties, some of which are beyond our control. Risks and uncertainties that could cause our actual results to differ materially from those indicated or implied by the forward-looking statements in this press release include, among other things: developments in the precision medicine industry; our future financial performance, results of operations or other operational results or metrics; development, analytical and clinical validation, timing and performance of future solutions by us and our competitors; commercial market acceptance for our solutions, including acceptance of preventive as well as diagnostic testing paradigms, and our ability to meet resulting demand; the rapidly evolving competitive environment in which we operate; third-party payer reimbursement and coverage decisions related to our solutions; risks related to data management, storage, and processing capabilities and our ability to integrate and deploy artificial intelligence and advanced data analytics technologies; our ability to protect and enhance our intellectual property; regulatory requirements, decisions or approvals (including the timing and conditions thereof) related to our solutions; reliance on third-party suppliers; risks related to data security, patient privacy, and compliance with healthcare data protection regulations as well as potential cybersecurity threats to our data platforms; our compliance with laws and regulations; the outcome of government investigations and litigation; risks related to our indebtedness; and our ability to hire and retain key personnel as well as risks, uncertainties, and other factors described in the section titled "Risk Factors" and elsewhere in our Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC) on March 3, 2026, and in our other filings we make with the SEC from time to time. We undertake no obligation to update any forward-looking statements to reflect changes in events, circumstances or our beliefs after the date of this press release, except as required by law. 

Caris Life Sciences Media:
Corporate Communications
CorpComm@CarisLS.com
214.294.5606

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/caris-life-sciences-publishes-study-showing-whole-exome-measurement-of-tumor-mutational-burden-results-in-increased-overall-survival-compared-to-estimates-from-targeted-gene-panels-302768392.html

SOURCE Caris Life Sciences

FAQ

What did Caris Life Sciences (CAI) announce about tumor mutational burden and pembrolizumab?

Caris Life Sciences announced study results showing Whole Exome Sequencing-based tumor mutational burden better predicts pembrolizumab benefit than targeted gene panels. According to Caris, WES-based TMB more reliably identifies patients likely to benefit and those unlikely to respond across multiple tumor types.

How often do targeted gene panels miscalculate tumor mutational burden compared with WES in the Caris (CAI) study?

Targeted gene panels miscalculated tumor mutational burden in an estimated 10–15% of patients compared with WES. According to Caris, discordance rates correlated with panel size and directly impacted pembrolizumab eligibility determinations based on TMB status across the analyzed patient population.

What survival benefit was associated with WES-based TMB in the Caris (CAI) pembrolizumab study?

In TMB-reliant patients, WES TMB-High status was linked to about five months longer median overall survival. According to Caris, discordant cases with WES TMB-High and panel TMB-Low outlived those classified as WES TMB-Low and panel TMB-High when treated with pembrolizumab.

How large was the Caris Life Sciences (CAI) dataset used to compare WES TMB and panel TMB?

The study used a clinico-genomic database of 26,756 pembrolizumab-treated patients evaluable for analysis. According to Caris, this large real-world dataset enabled robust comparison of Whole Exome Sequencing-measured TMB against commercially available targeted panel TMB estimates.

What is Caris MI Cancer Seek and how does it relate to TMB for CAI investors?

MI Cancer Seek is an FDA-approved tissue-based assay performing simultaneous Whole Exome and Whole Transcriptome Sequencing. According to Caris, it is the first assay with companion diagnostic indications for solid tumors that also provides quantitative reporting of tumor mutational burden for therapy selection.

Why does Caris (CAI) emphasize Whole Exome Sequencing as the gold standard for TMB testing?

Whole Exome Sequencing measures every protein-coding gene mutation that could generate neoantigens, providing a true TMB value. According to Caris, this comprehensive coverage makes WES a gold-standard approach for guiding pembrolizumab and immune checkpoint inhibitor treatment decisions across tumor types.